Bracket

Wayne, PA, United States
Wayne, PA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | May 16, 2017
Site: www.prnewswire.com

"We are pleased to introduce a cloud-based hosting option for SmartSupplies to our existing and new customers," said Jeff Kinell, CEO of Bracket. "The benefits of cloud hosting continue to present themselves, especially as clinical trials worldwide rely more on immediate collaboration across sites." Bracket's hosted SmartSupplies solution is competitively priced and provides a cost-effective alternative for sponsor companies deploying the enterprise solution. This cloud-based option allows sponsors to eliminate in-house hardware maintenance and management for a reduced IT footprint.  Other advantages include: The transition of SmartSupplies to the cloud is seamless for existing customers, causing no disruption to the end user. "Offering customers the option of cloud hosting for SmartSupplies was born out of necessity," said Kinell. "We want sponsors to focus their energy and efforts on running clinical trials, not on managing their IT infrastructure – and hosting SmartSupplies in the cloud will alleviate that burden." About Bracket Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket SmartSupplies™ is a proven platform for improving a clinical supply chain. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs. Learn more about Bracket at www.bracketglobal.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bracket-announces-launch-of-cloud-based-version-of-smartsupplies-300456964.html


"We're so pleased to introduce CUBE to the life sciences marketplace and are confident that its easy-to-implement nature will improve the process of managing clinical supplies," said Jeff Kinell, CEO at Bracket. "By deemphasizing requirement documents and prioritizing unique configuration needs, CUBE will undoubtedly evolve the paradigm of how sponsors collaborate to deploy IRT." The platform's iterative UAT process allows study teams to visualize the RTSM system during the kick off meeting. This accelerates timelines for sponsors and improves efficiency for CROs. CUBE also leverages Bracket's full RTSM platform, but streamlines the deployment of configuration profiles through automation. It's intended to support most trial design constructs. For more information, please visit www.bracketglobal.com/CUBE/. About Bracket Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket SmartSupplies™ is a proven platform for improving a clinical supply chain. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs. Learn more about Bracket at www.bracketglobal.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bracket-introduces-transformative-irt-solution-cube-to-biotech-and-pharma-sponsors-300464757.html


News Article | September 13, 2017
Site: www.prnewswire.com

Whitaker will be responsible for Bracket's global product strategy, management and innovation, technology development and engineering including architecture, user experience (UX), user interface (UI) and IT support functions. Whitaker will leverage his ten years' experience as co-founder and CEO of Greenphire, the first clinical technology to bring payment technology to the clinical environment. During his tenure at Greenphire, Whitaker invented and successfully commercialized the first clinical trial payment technologies. The web-based applications were built on top of a global technology infrastructure, which he and his team designed to support the unique needs of sponsors, clinical research organizations (CROs) and sites and scaled to support more than 500 clients globally. "Sam Whitaker joins Bracket with highly specific knowledge of clinical trial technology and a complete understanding of our technological vision," said Jeff Kinell, CEO of Bracket. "As we continue to solidify our position as a global leader in clinical trial technology and specialty services, it's imperative that we partner with our industry's most innovative minds to lead and implement industry-wide advancements." Prior to Greenphire, Whitaker worked in the product division of Citigroup, designing technology solutions across verticals. He graduated from the University of Pennsylvania. Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket SmartSupplies™ is a proven platform for improving a clinical supply chain. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs. Learn more about Bracket at www.bracketglobal.com.


Wesnes K.A.,Bracket | Wesnes K.A.,Northumbria University | Wesnes K.A.,Swinburne University of Technology | Edgar C.J.,Bracket
Current Opinion in Pharmacology | Year: 2014

Cognitive dysfunction characterizes all the various forms of dementia. Evidence is accumulating that all of the progressive neurodegenerative dementias, such as Alzheimer's disease (AD), are preceded by years, if not decades, of pathological cognitive decline. The limited effectiveness of the four current medications registered for AD together with the failure of dozens of programmes over the last decade has influenced the decision to evaluate treatment at earlier stages of the disease; even before any cognitive symptoms have appeared. However, it has to be acknowledged that treating mild cognitive impairment (MCI) as a prodrome for AD has also had very limited success. Nonetheless a more important problem in MCI research, and dementia in general, has to be laid at the door of the limited effectiveness of the cognitive tests employed. This problem will become even more severe for the latest research direction of treating preclinical AD because such individuals will have levels of cognitive abilities which are in the normal range; and thus many of the scales currently used in dementia research will not be sufficiently demanding to identify change over time. This paper reviews and discusses the methodology and instruments available for research and clinical practice in this major area; with a focus on the challenges involved in test selection and evaluation. © 2013 Elsevier Ltd.


Wesnes K.A.,Wesnes Cognition Ltd. | Wesnes K.A.,Northumbria University | Wesnes K.A.,Swinburne University of Technology | Annas P.,Bracket | And 3 more authors.
Alzheimer's Research and Therapy | Year: 2014

Introduction. Emerging evidence suggests that decreased adult hippocampal neurogenesis represents an early critical event in the course of Alzheimer's disease (AD). In mice, adult neurogenesis is reduced by knock-in alleles for human apolipoprotein E (ApoE) ∈4. Decreased dentate gyrus (DG) neural progenitor cells proliferation has been observed in the triple-transgenic mouse model of AD (3xTg-AD); this reduction being directly associated with the presence of amyloid-β (Aβ) plaques and an increase in the number of Aβ-containing neurons in the hippocampus. Cognitive tasks involving difficult pattern separations have been shown to reflect DG activity and thus potentially neurogenesis in both animals and man. This study involved the administration of a pattern separation paradigm to Alzheimer's patients to investigate relationships between task performance and both ApoE status and cerebrospinal fluid (CSF) Aβ42 levels. Methods. The CDR System pattern separation task involves the presentation of pictures that must later be discriminated from closely similar pictures. This paper presents pattern separation data from 66 mild to moderate AD patients, of which 50 were genotyped and 65 in whom CSF Aβ42 was measured. Results: ApoE ∈4 homozygotes were not compromised on the easy pattern separations compared with the other patients, but they were statistically significantly poorer at the difficult separations. In all patients CSF Aβ42 correlated significantly with the ability to make the difficult discriminations, but not easier discriminations. Pattern separation speed correlated negatively with CSF Aβ42, and thus the association was not due to increased impulsivity. Conclusions: These are, to our knowledge, the first human pattern separation data to suggest a possible genetic link to poor hippocampal neurogenesis in AD, as well as a relationship to Aβ42. Therapies which target neurogenesis may thus be useful in preventing the early stages of AD, notably in ApoE ∈4 homocygotes. © 2014 Wesnes et al.; licensee BioMed Central Ltd.


PubMed | Abbvie Inc. and Bracket
Type: Journal Article | Journal: Alcoholism, clinical and experimental research | Year: 2016

ABT-436, a potent and selective arginine vasopressin (AVP) type 1B receptor (V1B ) antagonist, has previously demonstrated basal hypothalamic-pituitary-adrenal (HPA) axis attenuation in man. A V1B antagonist is hypothesized as an alcohol-dependent treatment based on the role of the V1B receptor in stress regulation and the finding that stress is a trigger for relapse in alcoholics. A V1B antagonist has shown favorable effects in rat models of alcohol dependence. A single-dose clinical study was conducted to assess the potential for pharmacokinetic or pharmacodynamic interaction between ABT-436 and alcohol.Twenty moderate alcohol drinkers each received the 4 possible combinations of a single 1,000 mg ABT-436 dose (or matching placebo) and a single 0.5 g/kg alcohol dose (or placebo for alcohol) in a double-blind, randomized, 4-period crossover study. Plasma ABT-436 and blood alcohol levels were measured to assess pharmacokinetic interactions. A computerized cognitive test battery (CDR System), Bond-Lader Visual Analog Scales scales, and a postural stability test were used to measure the effects of alcohol and the potential interaction with ABT-436. The pharmacologic effect of ABT-436 was assessed by measuring serum cortisol.Neither ABT-436 nor alcohol affected the blood levels of the other. Alcohol reduced performance on 2 of 5 CDR System composite variables (power of attention, p = 0.002; quality of secondary episodic memory, p < 0.001), and decreased postural stability (p = 0.043). ABT-436 did not exacerbate those deleterious effects. ABT-436 reduced serum cortisol (p < 0.001), and alcohol did not significantly diminish this expected effect on the HPA axis.No pharmacokinetic or pharmacodynamic interaction between ABT-436 and alcohol was observed.


WAYNE, Pa., Dec. 7, 2016 /PRNewswire/ -- Bracket, a leading clinical trial technology and specialty services provider with expertise in Alzheimer's disease (AD), announced that its Scientific Advisory Board (SAB) has formed an AD sub-committee that will hold its inaugural meeting at the...


News Article | November 17, 2016
Site: www.prnewswire.com

WAYNE, Pa., Nov. 17, 2016 /PRNewswire/ -- Bracket, a leading clinical trial technology and specialty services provider, today announced the strategic acquisition of CLINapps Inc., an international software development and consulting firm that offers a comprehensive supply chain management...


News Article | November 17, 2016
Site: www.prnewswire.co.uk

WAYNE, Pennsylvania, Nov. 17, 2016 /PRNewswire/ -- Bracket, a leading clinical trial technology and specialty services provider, today announced the strategic acquisition of CLINapps Inc., an international software development and consulting firm that offers a comprehensive supply chain management product suite, designed to meet the unique requirements of biopharmaceuticals management. Effective today, CLINapps will combine its complimentary product offering with the Bracket eClinical suite to deliver a wider range of digital solutions across a trial. With synergies across their individual product offerings, Bracket and CLINapps maintain significant opportunities to revolutionize supply chain management. "CLINapps' strong technology fits squarely into Bracket's goal of transforming the way pharmaceutical companies manage data and interact with sites, investigators and patients," said Jeff Kinell, CEO of Bracket. "We are extremely excited to converge with CLINapps and work to improve how sponsor companies manage their clinical supply chain." CLINapps' product portfolio will be tightly integrated into Bracket's eClinical product suite, adding significantly to the Company's existing Randomization and Trial Supply Management (RTSM) capabilities. SmartSupplies, CLINapps' flagship enterprise clinical trial material management software solutions, will give Bracket the opportunity to manage end-to-end clinical inventory management for sponsors. Bracket's new integrated solution will advance areas of demand planning (forecasting), inventory management, cold chain distribution and controls electronic batch records and overall quality control on the labeling, release, assignment and return of clinical trial materials. "This acquisition marks an exciting opportunity for CLINapps and we are so pleased to have partnered with Bracket to help take our eClinical clinical supplies solutions to the next level," said Tim Elliott, CEO at CLINapps. "Upon recognizing the many synergies that existed, the opportunity to combine our conceptual and innovative solutions was an obvious answer to advancing this life sciences space." Founded in 1999, CLINapps maintains offices in San Diego, California and Hyderabad, India and will continue to operate these locations, expanding Bracket's presence in North America and Asia. To learn more about Bracket, visit www.bracketglobal.com. About CLINapps Established in 1999 with international offices, CLINapps is a fast-growing software development and consulting firm, creating state-of-the-art systems for the pharmaceutical and biotechnology industries. With a full time staff of highly skilled industry professionals, and a strong customer focus, CLINapps has a track record of providing high-quality end-to-end solutions for leading Biotechnology and Pharmaceutical companies. By leveraging our extensive domain knowledge and applying proven technologies, our mission-critical solutions give customers a distinct competitive advantage. About Bracket Bracket, with seven offices and more than 600 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs. Learn more about Bracket at www.bracketglobal.com.


Targum S.D.,Clintara LLC | Targum S.D.,BrainCells Inc. | Wedel P.C.,BrainCells Inc. | Robinson J.,BrainCells Inc. | And 5 more authors.
Journal of Psychiatric Research | Year: 2013

We compared scores from three different ratings methods in a clinical trial of patients with Major Depressive Disorder (MDD). The Quick Inventory of Depressive Symptoms (QIDS-SR16) was compared to site-based clinician and centralized (site-independent) ratings of the Inventory of Depressive Symptoms (IDSc30). An extracted QIDSc16 was used for a matched comparison with the QIDS-SR16. Patient self-ratings were more depressed at baseline than either site-based ratings (p = 0.131) or centralized ratings (p = 0.005), but significantly less depressed at the end of double-blind treatment than either site-based (p = 0.006) or centralized ratings (p = 0.014), and after 12 weeks (site-based ratings: p = 0.048; centralized ratings: p = 0.004). The matched comparisons with patient self-ratings revealed ICC of r = 0.55 (site-based raters) and r = 0.49 (centralized raters) at baseline. After baseline, the correlations between the two different clinician ratings and patient self-ratings improved to r-values between 0.78 and 0.89. At the end of double-blind treatment, site-based raters separated the combination treatment from placebo on the IDSc30 (p = 0.030) whereas neither centralized ratings nor patient self-ratings achieved statistical significance. Alternatively, patient self-ratings separated the combination treatment from buspirone (p = 0.030) whereas neither clinician rating method achieved significance. A " dual" scoring concordance range reduced the placebo response rate and increased the drug effect between the combination treatment and placebo. These findings reveal scoring variability between each of the three ratings methods and challenge the reliability of any single method to accurately assess symptom severity scores, particularly at baseline. The use of " dual" scoring criteria may help to confirm symptom severity scores and improve ratings precision, particularly prior to enrolling subjects into CNS trials. © 2013 Elsevier Ltd.

Loading Bracket collaborators
Loading Bracket collaborators